...
alvr-img

Allovir Inc, Common Stock

ALVR

NAQ

$0.46

-$0.04

(-7.92%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$85.25M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
556.86K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.74
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.45 L
$2.45 H
$0.46

About Allovir Inc, Common Stock

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameALVRSectorS&P500
1-Week Return-7.82%-2.82%0.15%
1-Month Return-15.05%-4.22%1.78%
3-Month Return-38.58%-9.52%8.7%
6-Month Return-41.77%-3.45%12.24%
1-Year Return-78.5%5.62%30.9%
3-Year Return-97.08%3.8%30.19%
5-Year Return-98.19%39.68%91.72%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue165.00K----[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue-73.00K1.12M2.56M398.00K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":2.85,"profit":true},{"date":"2021-12-31","value":43.55,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":15.52,"profit":true}]
Gross Profit165.00K(73.00K)(1.12M)(2.56M)(398.00K)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-44.24,"profit":false},{"date":"2021-12-31","value":-676.97,"profit":false},{"date":"2022-12-31","value":-1554.55,"profit":false},{"date":"2023-12-31","value":-241.21,"profit":false}]
Gross Margin100.00%(Infinity%)(Infinity%)(Infinity%)(Infinity%)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}]
Operating Expenses26.87M71.31M169.82M171.20M180.93M[{"date":"2019-12-31","value":14.85,"profit":true},{"date":"2020-12-31","value":39.41,"profit":true},{"date":"2021-12-31","value":93.86,"profit":true},{"date":"2022-12-31","value":94.62,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(26.70M)(71.31M)(169.82M)(171.20M)(181.33M)[{"date":"2019-12-31","value":-2670100000,"profit":false},{"date":"2020-12-31","value":-7130900000,"profit":false},{"date":"2021-12-31","value":-16981800000,"profit":false},{"date":"2022-12-31","value":-17120200000,"profit":false},{"date":"2023-12-31","value":-18133100000,"profit":false}]
Total Non-Operating Income/Expense4.93M2.85M178.00K4.10M(3.95M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":57.95,"profit":true},{"date":"2021-12-31","value":3.61,"profit":true},{"date":"2022-12-31","value":83.28,"profit":true},{"date":"2023-12-31","value":-80.23,"profit":false}]
Pre-Tax Income(23.84M)(69.78M)(170.96M)(168.97M)(190.54M)[{"date":"2019-12-31","value":-2383900000,"profit":false},{"date":"2020-12-31","value":-6978400000,"profit":false},{"date":"2021-12-31","value":-17095500000,"profit":false},{"date":"2022-12-31","value":-16897500000,"profit":false},{"date":"2023-12-31","value":-19054400000,"profit":false}]
Income Taxes(2.06M)(1.40M)1.01M(265.00K)(126.00K)[{"date":"2019-12-31","value":-205.06,"profit":false},{"date":"2020-12-31","value":-139.32,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-26.32,"profit":false},{"date":"2023-12-31","value":-12.51,"profit":false}]
Income After Taxes(21.77M)(68.38M)(171.96M)(168.71M)(190.42M)[{"date":"2019-12-31","value":-2177400000,"profit":false},{"date":"2020-12-31","value":-6838100000,"profit":false},{"date":"2021-12-31","value":-17196200000,"profit":false},{"date":"2022-12-31","value":-16871000000,"profit":false},{"date":"2023-12-31","value":-19041800000,"profit":false}]
Income From Continuous Operations(23.84M)(69.78M)(171.96M)(168.71M)(168.86M)[{"date":"2019-12-31","value":-2383900000,"profit":false},{"date":"2020-12-31","value":-6978400000,"profit":false},{"date":"2021-12-31","value":-17196200000,"profit":false},{"date":"2022-12-31","value":-16871000000,"profit":false},{"date":"2023-12-31","value":-16885800000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(21.77M)(68.38M)(171.96M)(168.71M)(190.42M)[{"date":"2019-12-31","value":-2177400000,"profit":false},{"date":"2020-12-31","value":-6838100000,"profit":false},{"date":"2021-12-31","value":-17196200000,"profit":false},{"date":"2022-12-31","value":-16871000000,"profit":false},{"date":"2023-12-31","value":-19041800000,"profit":false}]
EPS (Diluted)-(5.17)(2.74)(2.25)(1.67)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-517,"profit":false},{"date":"2021-12-31","value":-274,"profit":false},{"date":"2022-12-31","value":-225,"profit":false},{"date":"2023-12-31","value":-167,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ALVR
Cash Ratio 86.30
Current Ratio 86.78

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ALVR
ROA (LTM) -36.53%
ROE (LTM) -80.33%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ALVR
Debt Ratio Lower is generally better. Negative is bad. 0.01
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.99

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ALVR
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 0.48
Price/FCF NM
EV/R 0.00
EV/Ebitda 0.37

FAQs

What is Allovir Inc share price today?

Allovir Inc (ALVR) share price today is $0.46

Can Indians buy Allovir Inc shares?

Yes, Indians can buy shares of Allovir Inc (ALVR) on Vested. To buy Allovir Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ALVR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Allovir Inc be purchased?

Yes, you can purchase fractional shares of Allovir Inc (ALVR) via the Vested app. You can start investing in Allovir Inc (ALVR) with a minimum investment of $1.

How to invest in Allovir Inc shares from India?

You can invest in shares of Allovir Inc (ALVR) via Vested in three simple steps:

  • Click on Sign Up or Invest in ALVR stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Allovir Inc shares
What is Allovir Inc 52-week high and low stock price?

The 52-week high price of Allovir Inc (ALVR) is $2.45. The 52-week low price of Allovir Inc (ALVR) is $0.45.

What is Allovir Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Allovir Inc (ALVR) is

What is Allovir Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Allovir Inc (ALVR) is 0.48

What is Allovir Inc dividend yield?

The dividend yield of Allovir Inc (ALVR) is 0.00%

What is the Market Cap of Allovir Inc?

The market capitalization of Allovir Inc (ALVR) is $85.25M

What is Allovir Inc’s stock symbol?

The stock symbol (or ticker) of Allovir Inc is ALVR

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top